» Articles » PMID: 29563590

Successful Outcomes of Second Hematopoietic Stem Cell Transplantation with Total Nodal Irradiation and ATG Conditioning for Graft Failure in Adult Patients with Severe Aplastic Anemia

Overview
Specialty General Surgery
Date 2018 Mar 23
PMID 29563590
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Data regarding the optimal approach for second allogeneic hematopoietic stem cell transplantation (HSCT) after graft failure (GF) in acquired severe aplastic anemia (SAA) are still limited and heterogeneous. We examined 24 patients who underwent second HLA-matched sibling donor (MSD) peripheral blood HSCT for GF. The reconditioning regimen (TNI-750/ATG) consisted of a single dose of total nodal irradiation (TNI, 750 cGy) and antithymocyte globulin (ATG; Thymoglobulin, 1.25 mg/kg/day for 3 days). All but one patient achieved successful engraftment of neutrophils (median 12 days, range 5-21) and platelets (median 15 days, range 9-316). Two patients with subsequent secondary GF achieved successful engraftment after a third HSCT from the same MSD. After a median follow-up of 57.4 months (range, 11.2-155.2), the 5-year overall survival and failure-free survival were 95.7% (95% confidence interval [CI] 87.7-100%) and 87.5% (95% CI 75.2-100%), respectively. One patient developed grade II acute graft-versus-host disease (GVHD), and the 2-year cumulative incidence of chronic GVHD was 23.5% (95% CI 8.1-43.5%). This study demonstrated successful outcomes following a second MSD HSCT in SAA after GF, and the results suggest TNI-750/ATG is a feasible reconditioning option. Future studies with larger cohorts will validate our results.

Citing Articles

Ovarian tissue cryopreservation after graft failure of allogeneic hematopoietic stem cell transplantation: first report and literature review.

Zhang J, Li X, Liang R, Duan S, Yang X, Hou Y Front Endocrinol (Lausanne). 2024; 15:1367241.

PMID: 39253581 PMC: 11382424. DOI: 10.3389/fendo.2024.1367241.


Successful outcomes of second hematopoietic stem cell transplantation for graft failure in pediatric patients with severe aplastic anemia.

He M, Gui R, Zu Y, Li Z, Wang D, Mao Y Sci Rep. 2022; 12(1):10528.

PMID: 35732877 PMC: 9217791. DOI: 10.1038/s41598-022-14665-1.


Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders.

Albert M, Sirin M, Hoenig M, Hauck F, Schuetz C, Bhattacharyya R Bone Marrow Transplant. 2021; 56(9):2248-2258.

PMID: 33967276 PMC: 8106764. DOI: 10.1038/s41409-021-01323-9.


[Tumor necrosis factor-α and transforming growth factor-β balance liver stem cell differentiation in cholestatic cirrhosis].

Yang B, Luo Q, Kang Q, Wang J, Xiao C, Li Z Nan Fang Yi Ke Da Xue Xue Bao. 2018; 38(4):375-383.

PMID: 29735435 PMC: 6765666.

References
1.
Stucki A, Leisenring W, Sandmaier B, Sanders J, Anasetti C, Storb R . Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood. 1998; 92(8):2742-9. View

2.
Champlin R, Horowitz M, van Bekkum D, Camitta B, Elfenbein G, Gale R . Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989; 73(2):606-13. View

3.
Weisdorf D, Verfaillie C, Davies S, Filipovich A, Wagner Jr J, Miller J . Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Blood. 1995; 85(12):3452-6. View

4.
Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View

5.
Ramsay N, Kim T, McGlave P, Goldman A, Nesbit Jr M, Krivit W . Total lymphoid irradiation and cyclophosphamide conditioning prior to bone marrow transplantation for patients with severe aplastic anemia. Blood. 1983; 62(3):622-6. View